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Abstract
Introduction: A feature which makes stem cells promising candidates for cell therapy is their ability to migrate
effectively into damaged or diseased tissues. Recent reports demonstrated the increased motility of human
mesenchymal stem cells (hMSC) grown under hypoxic conditions compared to normoxic cells. However, the
directional migration of hMSC cultured in hypoxia has not been investigated. In this study we examined the in
vitro transmembrane migration of hMSC permanently cultured in hypoxia in response to various cytokines. We also
studied the involvement of RhoA, a molecule believed to play an essential role in the migration of MSC via
reorganization of the cytoskeleton.
Methods: We compared the directional migration of human hMSCs grown permanently under normal (21%,
normoxic) and low O2 (5%, hypoxic) conditions until passage 4 using an in vitro transmembrane migration assay. A
series of 17 cytokines was used to induce chemotaxis. We also compared the level of GTP-bound RhoA in the cell
extracts of calpeptin-activated hypoxic and normoxic hMSC.
Results: We found that hMSC cultured in hypoxia demonstrate markedly higher targeted migration activity
compared to normoxic cells, particularly towards wound healing cytokines, including those found in ischemic and
myocardial infarction. We also demonstrated for the first time that hMSC are dramatically more sensitive to
activation of RhoA.
Conclusions: The results of this study indicate that high directional migration of hMSCs permanently grown in
hypoxia is associated with the enhanced activation of RhoA. The enhanced migratory capacity of hypoxic hMSC
would further suggest their potential advantages for clinical applications.
Introduction
Mesenchymal stem cells (MSC) or multipotent stromal
cells are non-hematopoietic progenitor cells with potential
to differentiate into multiple lineages - adipogenic, osteo-
genic and chondrogenic. They are known to possess many
features which make them an attractive candidate for stem
cell therapy or drug delivery applications. Specifically, it
has been established that MSC are capable of self-renewal
[1], secreting a wide spectrum of cytokines and factors [2],
and also have a unique ability to fuse with damaged cells
[3-5]. Furthermore, some data indicate that MSC are able
to migrate in vivo to the site of injury [6-8].
It is important to preserve these characteristics during
tissue culture expansion, a necessary step towards the gen-
eration of clinically significant cell numbers. One of the
major complications at this step is spontaneous cell differ-
entiation, which can occur particularly in the presence of
bovine serum. A possible approach to alleviate this pro-
blem is cultivation of MSC in a low oxygen environment.
The underlying premise is that in vivo MSC reside in an
environment with a relatively low oxygen (O2) concentra-
tion [9-11], which makes hypoxic tissue culture conditions
beneficial. In particular, it has been shown that hypoxic
MSC maintain significantly higher colony-forming unit
capabilities and higher levels of stem cell-related genes
[12]. They exhibit higher levels of osteoblastic and adipo-
cytic differentiation markers (upon induction of the cells)
as well as increased total protein levels compared to MSC
* Correspondence: gvertelov@stemedica.com; akharazi@stemedica.com
’Stemedica’ Cell Technologies, 5375 Mira Sorrento Place, Suite 100, San
Diego, CA 92121, USA
Vertelov et al. Stem Cell Research & Therapy 2013, 4:5
http://stemcellres.com/content/4/1/5
© 2013 Vertelov et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
, Ludmila Kharazi, M G Muralidhar, Givon Sanati, Timothy Tankovich and Alex Kharazi
cultured under 20% O2 (normoxic) conditions [13]. Sev-
eral reports indicated that MSC cultured in hypoxia,
demonstrate increased proliferation activity [13-16]. It has
been speculated that oxygen concentration regulates the
intricate balance between cellular proliferation and com-
mitment towards differentiation, impacts ‘stemness’ of the
MSCs [17]. Overall, it appears that the hypoxic environ-
ment is promoting a genetic program maintaining the
undifferentiated and multipotent status of MSCs [12,18].
Migration to the sites of injury is an essential and
characteristic feature of MSC [6-8] which is mediated by
several regulators such as the Rho family of GTPases. In
particular, the RhoA signaling cascade is believed to
play an essential role in migration of MSC [19]. It is one
of the best characterized members of the Rho family
and has been shown to control cytoskeletal activation in
many adherent cells, including MSC. RhoA regulates
microtubule and actin assembly, the formation of stress
fibers and cell adhesion, regulation of contraction and
retraction. Therefore, the RhoA signaling cascade is
believed to play an essential role in migration of MSC.
In this paper, we compared the in vitro directional
migration of human MSC (hMSC) permanently cultured
under normal (21%) and low O2 (5%) conditions (from
now on called ‘normoxic’ and ‘hypoxic’, respectively).
Recent reports demonstrated the increased motility of
hMSC grown under hypoxic conditions compared to
normoxic cells [20]. However, the directional migration
of hMSC cultured in hypoxia has not been investigated.
A series of soluble chemokines, growth factors and
inflammatory cytokines were chosen as chemoattractants
in the in vitro transmembrane migration assay. We found
that hMSCs cultured in hypoxia have higher motility
compared to the normoxic hMSCs towards most of the
studied factors, particularly towards wound healing cyto-
kines and cytokines found in ischemic brain and
infarcted myocardium milieu. In an attempt to under-
stand the underlying reasons for increased migration of
hypoxic hMSC we measured RhoA activation in the cells.
We discovered a markedly enhanced activation of RhoA
in hypoxic MSC suggesting that high hMSC migration
may occur via increased sensitivity to RhoA activation.
Methods
Cell culture
The mononuclear MSC fraction was isolated from a
human bone marrow purchased from Lonza (the marrow
was obtained from a healthy volunteer with appropriate
informed consent and under ethical approval according to
Lonza (Walkersville, MD, USA). The cells were cultured
in tissue culture dishes (TCDs) in hMSC growth medium
(hMSCGM): (D)MEM/F12+Glutamax™-I basal medium
(LifeTechnologies, Grand Island, NY, USA) supplemented
with 15% bovine growth serum (HyClone, Logan, UT,
USA) and basic fibroblast growth factor (bFGF) (Pepro-
Tech, Rocky Hill, NJ, USA). For normoxic oxygen condi-
tions (21% O2) cells were incubated in a standard
humidified incubator at 37°C and 5% CO2. The hypoxia
culturing was performed in a humidified 5% O2 and 5%
CO2 incubator at 37°C.
Cell characterization
Marker Expression
Cells were stained with appropriate antibodies conju-
gated to R-Phycoerythrin (PE) (BD Biosciences, San Jose,
CA, USA) and expression scored by flow cytometry using
standard protocols. The antibodies used were CD14,
CD19, CD34, CD45, CD 73, CD90, CD105, CD166,
HLA-DR and isotype control, diluted according to the
manufacturers’ recommendations.
Differentiation
For adipocyte and osteocyte differentiation, cells were
seeded at high density and allowed to grow to confluence.
The media was removed and replaced with appropriate
differentiation media (Life Technologies). They were cul-
tured further for two weeks with intermittent media
changes. Adipocytes were visibly recognized as lipid dro-
plets in cells. Osteocyte cultures were stained with Ali-
zarin Red [21]. Chondrocyte differentiation was
accomplished as a micromass, tissues were embedded
and sectioned in a cryostat. The sections were fixed,
washed and stained with Alcian Blue [22].
Cytokine secretion
Passage 3 cells were seeded at 700 cells/cm2 and cultured
for seven to nine days in either normoxia or hypoxia, with
intermittent media change. When the cultures reached
approximately 70% confluence, media was replaced and
cultures further incubated for 24 hours. Media superna-
tants were harvested and stored at -20°C. Cells were har-
vested and counted. Vascular endothelial growth factor
(VEGF), stromal cell-derived factor-1a (SDF-1a) and
angiopoietin-1 amounts in supernatants were determined
by ELISA (R & D Systems, Minneapolis, MN, USA) and
normalized to amounts secreted by one million cells.
Colony Forming Unit - Fibroblasts (CFU-F)
Human bone marrow derived hMSCs were expanded
under normal (normoxic) and 5% oxygen (hypoxic) condi-
tions up to passage 2 and frozen in liquid nitrogen. A fro-
zen stock of MSCs was thawed at 37°C, diluted with
complete medium and recovered by centrifugation to
remove dimethyl sulfoxide (DMSO). The cells were sus-
pended in medium and plated at 100 cells per 9 cm TCD
for CFU assay according to the following design: 1) nor-
moxic hMSCs assessed under normoxic conditions, 2)
normoxic cells assessed in the hypoxic environment, and
3) hypoxic cells assessed under hypoxic conditions (total
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of three experimental groups, five dishes per group). The
cultures were stained 14 days later with Giemsa and the
number of colonies (CFU-F) was manually counted. The
experiment was repeated three times.
Chemotaxis assay
A migration assay was performed in 48- or 96-well Corn-
ing Costar transwell chambers with porous polycarbonate
membranes with a pore size of 5 um (Fisher Scientific,
Rockville, MD, USA). hMSC at passage 4 were resus-
pended at 1 × 106/mL in the migration medium supple-
mented with 1% BSA and insulin transferrin selenium
(ITS) and seeded in the upper chamber. The following
human recombinant proteins were used as chemoattrac-
tants in the lower compartment: hepatocyte growth
factor (HGF), platelet-derived growth factor-AB (PDGF-
AB), epidermal growth factor (EGF), VEGF-121, basic
fibroblast growth factor (bFGF), insulin-like growth fac-
tor (IGF-1), macrophage inflammatory protein-3b (MIP-
3b), macrophage inflammatory protein-1a (MIP-1a),
B cell attracting chemokine-1 (BCA-1), regulation upon
activation normal T cell express sequence (RANTES),
growth regulated proteina (GROa), fractalkine, SDF-1a,
IL-1b, IL-6, IL-8, TNF-a (PeproTech). The concentration
of each cytokine was optimized to ensure maximal cell
migration through the porous membrane. The concen-
trations were: 40 ng/mL HGF, 10 ng/mL PDGF-AB,
10 ng/mL EGF, 10 ng/mL VEGF-121, 10 ng/mL bFGF,
30 ng/mL IGF-1, 10 ng/mL MIP-3b, 50 ng/mL MIP-1a,
5 ng/mL BCA-1, 150 ng/mL RANTES, 50 ng/mL GROa,
300 ng/mL Fractalkine, 150 ng/mL SDF-1a, 10 ng/mL
IL-1b, 100 ng/mL IL-6, 50 ng/mL IL-8 and 50 ng/mL
TNF-a. The chambers were incubated for four hours at
37°C in hypoxic or normoxic incubators. The cells from
the top side of the membrane chamber were removed
and the migrated cells on the underside of the membrane
were completely dislodged by incubating the membrane
inserts in 15 mM ethylenediaminetetraacetic acid
(EDTA) for 20 minutes. All migratory cells were lysed
with Triton X-100 and detected by CyQuant® GR dye
(Life Technologies) according to a standard protocol
(Cell Biolabs, San Diego, CA, USA). Results were
expressed as the mean number of net migrated cells over
control cells (basal migration without chemotactic stimu-
lus). Each condition was tested in four wells; each experi-
ment was repeated four times.
RhoA activation assay
Passage 2 cells were seeded at 2,000 cells/cm2 and cul-
tured for seven to nine days in either normoxic or hypoxic
incubators, with intermittent media change. When the
cultures reached approximately 70% confluence they were
harvested and re-plated at the same concentration and
cultured until reaching a confluence of 70% to 80%. For
activation of RhoA, the growth media were changed to
serum-free media containing either 100 ug/mL CN01 (cal-
peptin, Cytoskeleton, Denver, CO, USA) (activated MSC)
or 1% DMSO (non-activated MSC), according to the man-
ufacturer’s instructions. After 10 minutes of incubation
the cells were immediately put on ice and all consecutive
manipulations were done on ice. To determine active
RhoA (guanosine triphosphate (GTP)-bound) levels, a
commercially available ELISA kit (G-LISA, Cytoskeleton)
was utilized on the whole cell extracts according to the
manufacturer’s instructions. The results were normalized
to the total protein level. Each experiment was repeated
four times in 15 cm TCDs, two dishes per experimental
group.
Hypoxia inducible factor -1 activity assay
Passage 2 cells were seeded at 2,000 cells/cm2 and cul-
tured for seven to nine days in either normoxic or
hypoxic incubators with intermittent media change.
When the cultures reached approximately 70% conflu-
ence they were harvested and re-plated at the same con-
centration and cultured until reaching a confluence of
70% to 80%. After that time, cells were immediately put
on ice and the nuclear extracts were collected according
to the manufacturer’s protocol (Nuclear Extract Kit,
Active Motif, Carlsbad, CA, USA). To determine acti-
vated hypoxia inducible factor-1 (HIF-1) levels, a com-
mercially available ELISA kit (Active Motif) was utilized
on the nuclear extracts according to the manufacturer’s
instructions. The results were normalized to the number
of cells. Each experiment was performed four times in 15
cm TCDs, three dishes per experimental group. The spe-
cificity of the assay was confirmed by using the wild-type
consensus oligonucleotide which competes for HIF-1
binding and the mutated consensus oligonucleotide,
which does not bind HIF-1.
Statistics
Data are representative of three or more independent
experiments and presented as mean ± SEM. Statistical sig-
nificance was assessed using Student’s unpaired t-Tests
(Microsoft Excel). Probability values of less than 0.05 were
considered significant.
Results
Cell characterization and differentiation, VEGF production
Both normoxia and hypoxia cultured hMSC stained posi-
tively for CD73, CD90 and CD105, a set of markers
required to be expressed according to minimal criteria
for defining multipotent MSC adopted by the Interna-
tional Society for Cell Therapy [23]. Also, both cells types
did not express hematopoietic markers CD14 (mono-
cytes/macrophages), CD19 (B cells), CD34 (progenitors/
endothelial cells) or CD45 (leukocytes), or HLA-DR.
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Flow cytometry analysis revealed no difference in the
expression of surface markers between hypoxic and nor-
moxic hMSC. The fraction of HLA-DR-positive cells
never exceeded 2%. Cell cultures grown in hypoxia and/
or normoxia differentiated into adipocytes, osteocytes
and chondrocytes and secreted a number of cytokines.
hMSCs grown in hypoxia secreted greater amounts of
some cytokines such as VEGF, SDF-1, and angiopoietin-1
(data not shown).
Colony Forming Unit - Fibroblasts
The effect of hypoxia on clonogenicity of hMSC was
evaluated by the CFU-F assay. Hypoxic and normoxic
hMSC were seeded in TCDs at a density of 1.66 cells/
cm2 and incubated for 14 days. Initially, the assay was
performed in the same oxygen environment as the origi-
nal cell culture. The results showed dramatically higher
CFU-F numbers (1.7 fold difference) produced by
hypoxic hMSC (Figure 1).
It has been shown that MSC demonstrate higher CFU-F
when placed in hypoxic conditions [13,24,25]. Therefore,
to rule out the effect of the hypoxic assay environment,
the normoxic cells were assessed for colony formation
under hypoxic conditions. We observed a 20% increase in
the number of colonies produced by normoxic hMSC in
hypoxia compared to a normoxic environment. However,
the number remained 50% (P = 4 × 10-6) lower than long
term cultured hypoxic hMSC.
These data confirmed the notion that hMSC grown per-
manently in hypoxia have higher clonogenic potential
compared to normoxic cells. It is unlikely that the
observed phenomenon can be explained by hypoxic condi-
tions during the assay. It may rather reflect the increased
number of immature stem cells in the population of
hypoxic hMSC.
Migration
Next, we studied the migration potential of hypoxic and
normoxic hMSCs in vitro, using a transmembrane assay.
Three groups of molecules were used as chemoattractants:
growth factors (HGF, PDGF-AB, EGF, VEGF-121, bFGF,
IGF-1), chemokines (MIP-3b, MIP-1a, BCA-1, RANTES,
GROa, Fractalkine, SDF-1a), and inflammatory cytokines
(IL-1b, IL-6, IL-8, TNF-a). The assay was performed in
the same oxygen environment as the original cell culture.
Figure 2 (A, B, C) demonstrates that for the most part
the number of migrating hypoxic hMSC was significantly
higher compared to normoxic cells (HGF, EGF, VEGF-
121, bFGF, BCA-1, RANTES, SDF-1a, IL-1b, IL-6, TNF-
a, P < < 0.05), It should be noted that IL-8 was the only
cytokine that showed some inhibitory effect on migration
of hypoxic hMSC, although the difference did not reach
significance between the oxygen groups (P = 0.87). Also,
significance was not reached in the case of IGF-1 and
MIP-3b (P = 0.21 and 0.25, respectively). However, all
three cytokines (IL-8. IGF-1 and MIP-3b) stimulated a sta-
tistically significant increase in migration over the base
line in both hypoxic and normoxic hMSC.
It is interesting to observe that the migration towards
the growth factors was more prominent compared to
inflammatory cytokines and chemokines. On average,
280% more cells migrated towards HGF, PDGF-AB and
EGF than towards inflammatory cytokines and chemo-
kines. SDF-1a demonstrated the highest chemotactic
activity among them, being as stimulating for cell migra-
tion as the most active growth factors.
To rule out the effect of the assay environment on
migration of hMSC, the normoxic cells were transferred
for the assay into hypoxia. Although we observed more
migrating cells in normoxic hMSC under hypoxic condi-
tions compared to normoxia, the numbers remained sig-
nificantly lower (P < 0.05) than in long term cultured
hypoxic hMSC for most of the cytokines tested except
for PDGF-AB, MIP-1a, BCA-1 and GROa (P > 0.05, data
not shown).
In addition, we found that the increased migration of
hypoxic cells was particularly noticeable toward cytokines
involved in the wound healing process such as EGF,
bFGF, VEGF-121, IL-1b, IL-6 and TNF-a (Figure 2). All
of them have been shown to participate in a complex sig-
naling network leading to wound repair and regeneration
[26].
Taken together, our data suggest that the in vitro
migration of hMSCs permanently grown in hypoxia is
significantly higher compared to hMSC grown under
normoxic conditions.
Evaluation of mechanisms involved in the enhanced
hypoxic hMSC migration
Role of RhoA in hMSC migration
First, we explored the involvement of RhoA in the
observed phenomena. As has been already mentioned in
the Introduction, the RhoA signaling cascade is believed
to play an essential role in the migration of MSC [19]. It
controls cytoskeletal activation in many cell types includ-
ing MSC [27,28]. To become functional RhoA needs to
be activated by a variety of growth factors, cytokines,
adhesion molecules, hormones, integrins, G-proteins and
other biologically active substances [29]. In vitro it can be
activated by synthetic molecules, such as CN01 (calpep-
tin), which was used in this study. We measured the con-
centration of GTP-bound (active) RhoA in the whole cell
extracts of activated hypoxic and normoxic hMSC. The
activation of the hMSC for the assay was performed in
the same oxygen environment as the original cell culture.
The results showed that upon activation of hMSC
with CN01 the level of GTP-bound RhoA in hypoxic
cells is significantly higher (1.7-fold increase) than in
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normoxic cells (Figure 3). It is noteworthy that the level
of GTP-bound RhoA in non-activated hMSC was not
different between the groups (P = 0.66), suggesting that
long term cultivation in hypoxia enhances activation of
RhoA in hMSC.
Overall, these data, together with the observed increased
migration of hypoxic hMSC, support the involvement of
RhoA in hMSC migration. Moreover, we speculate that
hypoxia may lead to greater hMSCs migration via
increased sensitivity to RhoA activation.
Active HIF-1 and RhoA activation in hypoxic hMSC
To study how hypoxia may lead to enhanced RhoA activa-
tion we assayed the activity of HIF-1 in hypoxic and
normoxic hMSCs. It has been established that hypoxia-
activated HIF-1 is a major contributor to cell transcription
alteration [30]. Activated HIF-1 was shown to be a poten-
tial upstream regulator of RhoA activation in MSC [19,31].
In this study, we measured HIF-1 activity in hypoxic
and normoxic cells using the TransAM method (Activ
Motif). This approach allows detecting only activated
HIF-1 in cell nuclear extracts. The specificity of the
assay was confirmed by adding either the wild-type or
mutated consensus oligonucleotides to the tested sam-
ples. The addition of the wild-type nucleotide to the
tested samples completely suppressed HIF-1 binding to
the probe immobilized on the assay plate. Conversely,
the addition of the mutated oligonucleotide did not
affect the assay results, thus confirming the specificity of
the testing method.
We found that normoxic hMSCs demonstrate very low
(undetectable) levels of active HIF-1, unlike hypoxic cells
which have accumulated large amounts of this factor
(8.4 ng per 1 million cells) (Figure 4). The data suggest
that hypoxia-activated HIF-1 may be involved in
enhanced activation of RhoA in hypoxic hMSC. Thus, it
can be speculated that high activity of HIF-1 in hypoxic
hMSC leads to increased cell motility via the stimulated
activation of RhoA.
Figure 1 Clonogenicity of bone marrow derived hMSC determined in CFU-F assay. hMSCs grown and assayed under normal O2 (21%) -
Normoxic MSC in normoxia, grown and assayed in low O2 (5%) - Hypoxic MSC in hypoxia, grown in normoxia and assayed in hypoxia - Normoxic
MSC in hypoxia. The assay was performed in 9 cm tissue culture dishes, five dishes per experimental group. The cultures were terminated 14 days after
initiation. The dishes were stained with Giemsa and the colonies (CFU-F) were manually counted. Each experiment was repeated three times.
Columns represent the average number of colonies per plate from all three experiments combined (n = 15). The bars represent 1 SEM. × - P < 0.05,
×× - P < 0.0001. CFU-F, colony forming unit fibroblasts; hMSC, human mesenchymal stem cells; SEM, standard error of the mean.
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Figure 2 Migration capacity of hypoxic and normoxic hMSCs towards growth factors, chemokines and inflammatory cytokines. In vitro
migration was assayed in transwell plates with porous polycarbonate membranes (pore size: 5 um). Columns represent the difference between
the mean numbers of induced and spontaneously migrating cells (no chemoattractant added). Each condition was tested in four wells; each
experiment was repeated four times. The bars represent 1 SEM from four independent experiments combined (n = 16). × - P > 0.05, ×× - P <
0.05. (A): Migration of (BM) hMSC towards growth factors, (B): Migration of (BM) hMSC towards chemokines, (C): Migration of (BM) hMSC towards
inflammatory cytokines. hMSC, human mesenchymal stem cells; SEM, standard error of the mean.
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Discussion
In this paper, we provide the evidence for higher in vitro
targeted migration of hMSC cultured under hypoxic con-
ditions compared to the cells grown in normal oxygen
toward most of the tested cytokines. Previous studies
showed the enhancing effect of short term exposure to
hypoxia on migration of MSC [15,19,28,32-34]; an
increase in cell velocity and Euclidian distance on a series
of matrices for the hMSC cultured in 2% hypoxia has
also been shown [20]. To our knowledge we are the first
to report higher targeted migration of hMSC grown in
hypoxia for the entire culturing period.
We tested migration toward the factors from three
major groups - growth factors, chemokines and inflamma-
tory cytokines - since hMSCs have been shown to express
an array of functional receptors for those molecules
[35-38]. We found that all 17 cytokines tested in this study
mediated in vitro cell migration of hMSC, with the least
activity among chemokines and the most among growth
factors, which is in agreement with other studies [35-37].
In addition, we noticed that hypoxic cells are more
responsive to cytokines often present in a wound milieu
(Figure 2). The most important among them are the EGF
family, the fibroblast growth factor family, VEGF-121,
PDGF-AB, the IL family and TNF-a [26]. The enhanced
migration of hMSCs toward the wound healing cytokines
can potentially accelerate the formation of new tissue and
ultimately wound closure.
In addition, we found a significantly better migration of
hypoxic cells toward such factors as HGF, SDF-1a, the IL
family cytokines and TNF-a. It is tempting to speculate
that this feature may lead to better in vivo homing of
long term hypoxia-cultured hMSCs to the sites of infarct
and stroke since those factors are abundant at the sites of
ischemic injury [39-43].
It is noteworthy that migration of normoxic hMSC
transferred for the assay into a hypoxic environment was
still lower than in hypoxic cells, but higher than in nor-
moxic cells assessed in normoxia (data not shown) con-
firming the known stimulating effect of acute hypoxia on
the migration of MSC. It has been shown that hypoxic
pre-conditioning increases MSC migration [32] due, at
least in part, to up-regulated expression of the chemokine
receptors CX3CR1 and CXCR4 [15], as well as the c-Met
receptor for HGF [33]. It is possible that the increased
migration of cells permanently cultured in hypoxia can be
explained by up-regulation of a series of receptors. How-
ever, we believe that the major reason for the mentioned
phenomenon is the undifferentiated status of hypoxic
MSC.
The latter notion is supported by the analysis of CFU-F
efficiency, which demonstrated that hypoxic hMSC have
increased CFU-F, compared to similar cells grown under
normoxic conditions (Figure 1). Normoxic cells assayed
for CFU-F in hypoxia still produced a significantly lower
number of colonies compared to hypoxic cells ruling out
the effect of assay environment. Rather, the higher number
of CFU-F in hypoxic cells may be due to the accumulation
Figure 3 RhoA activation by calpeptin measured by G-LISA in
hypoxic and normoxic hMSCs. The activation was performed in the
same oxygen environment as the original cell culture. Cells were 80%
to 90% confluent when treated with 0.1 mg/mL of calpeptin for 10
minutes, then lysed and the lysates were subjected to the G-LISA assay
(activated MSC). The control cells were treated with the media, which
did not contain calpeptin (non-activated MSC). The assay was
performed in two dishes per experimental group; each experiment
was repeated four times. Data are presented with the subtracted
background (medium alone). Columns represent the average of four
experiments combined (n = 8). The bars represent 1 SEM. × - P < 0.05,
×× - P < 0.01. MSC, mesenchymal stem cells; SEM, standard error of
the mean.
Figure 4 Activated HIF-1 measured by TransAM HIF-1 ELISA in
hypoxic and normoxic hMSCs. Columns represent mean amounts
of activated HIF-1 normalized to amounts per million harvested
cells. The assay was performed in three dishes per experimental
group; each experiment was repeated four times. Data are
presented with the subtracted background (medium alone).
Columns represent the average of four experiments combined (n =
12). The bars represent 1 SEM. ×- P < < 0.01. ELISA, enzyme-linked
immunosorbent assay; HIF-1, hypoxia inducible factor-1; hMSCs,
human mesenchymal stem cells; SEM, standard error of the mean.
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of immature stem cell progenitors as previously proposed
[12].
Perhaps the most significant finding of this study is the
enhanced activation of RhoA in hypoxic hMSC. The
RhoA signaling cascade is believed to play an essential role
in the migration of MSC [19]. The family of RhoGTPases
directs a variety of cell responses including cell migration,
adhesion, transcription, growth and so on [44]. It controls
cytoskeletal activation in many cell types including MSC
[27,28]. We demonstrated that upon activation with CN01
the increase of GTP-bound RhoA over non-activated cells
is considerably higher in hypoxic hMSC compared to nor-
moxic cells (3-fold and 1.5-fold, respectively). It remains
to be investigated whether this phenomenon is true for
other types of stem cells reflecting their undifferentiated
status. The precise mechanism of the observed difference
in sensitivity is unclear. Recently, it has been shown that
HIF-1 and RhoA cross-talk suggesting the role of HIF-1 in
hypoxic regulation of MSC migration through the RhoA
signaling cascade [19,31].
HIF-1 is one of the key regulators of oxygen homeosta-
sis [45]. HIF-1 is a heterodimeric protein that consists of
two subunits, HIF-1a and HIF-1b. While HIF-1b is con-
stitutively expressed, the expression of HIF-1a is lower in
normoxic conditions (O2 > 6%) due to its hydroxylation
and degradation. In hypoxia (O2 < 6%) both subunits,
HIF-1a and b, survive degradation and form an active
HIF-1 heterodimer, which binds to the HRE in the cell
nucleus [46]. It has been shown that artificial stabilization
of HIF-1 in normoxia by desferrioxamine (DFO), as well
as pre-conditioning in 1% hypoxia result in attenuation
of RhoA activation [19,31] suggesting that activated HIF-
1 is a potential upstream regulator of RhoA. We found
that both activated HIF-1 and GTP-bound RhoA were
elevated in long term hypoxic cells, reflecting a strong
link between HIF-1 and activation of RhoA in hypoxic
hMSC.
It should be noted that the RhoA activation pattern
observed by Raheja et al. [19] for hMSC pre-conditioned
in 1% hypoxia or treated with DFO (state close to anoxia)
is different compared to the data presented in this paper.
It can be due to the fact that hypoxia pre-conditioning,
which reflects the acute cellular response to hypoxia [33]
rather than cell differentiation status, is substantively dif-
ferent from permanent cell cultivation in the low O2 envir-
onment. Also, 0%/1% and 5% oxygen concentrations may
potentially have different effects on MSCs physiology [18].
Therefore, we believe it is difficult to directly compare our
data to the results reported by Raheja et al. [19].
Conclusions
In conclusion, in this paper we confirmed the notion that
hMSC cultured under hypoxic conditions preserve their
undifferentiated status as judged by higher colony-forming
potential and increased in vitro targeted migration. In
addition, for the first time, we demonstrated that hypoxic
MSC compared to normoxic are dramatically more sensi-
tive to activation of RhoA which may contribute to the
observed high migration. Finally, we found that hypoxic
hMSCs migrate better towards wound healing cytokines
and cytokines found in an ischemic tissue milieu sugges-
ting their potential therapeutic advantages over normoxic
cells.
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insulin transferrin selenium; MIP-1α: macrophage inflammatory protein-1α;
MIP-3β: macrophage inflammatory protein-3β; PDGF-AB: platelet-derived
growth factor-AB; RANTES: regulation upon activation normal T cell express
sequence; SDF-1α: stromal cell-derived factor-1α; TCD: tissue culture dishes;
TNF-α: tumor necrosis factor- α; VEGF-121: vascular endothelial growth
factor-121.
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